Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526655 | 0.93 | KEAP1 (0.48) | KEAP1SMN1; SMN2HRH3HPGDDUSP3 | |
| SCHEMBL5238996 | 0.89 | SLC6A2 (0.39) | KEAP1SMN1; SMN2HRH3SLC6A2SLC6A4 | |
| SCHEMBL9085403 | 0.87 | SLC6A2 (0.38) | KEAP1SMN1; SMN2HRH3SLC6A2SLC6A4 | |
| SCHEMBL643894 | 0.85 | HRH3 (0.44) | SMN1; SMN2HRH3MAPTSIGMAR1 | |
| SCHEMBL15515230 | 0.81 | KEAP1 (0.42) | KEAP1SMN1; SMN2HPGDDUSP3SLC6A2 | |
| SCHEMBL5460755 | 0.79 | KEAP1 (0.40) | KEAP1SMN1; SMN2HRH3HPGDDUSP3 | |
| SCHEMBL10713621 | 0.76 | KCNH2 (0.39) | SMN1; SMN2HRH3MAPTHPGDPOLB | |
| SCHEMBL5622310 | 0.74 | KEAP1 (0.39) | KEAP1SMN1; SMN2HPGDDUSP3POLB | |
| SCHEMBL17377315 | 0.74 | KEAP1 (0.62) | KEAP1SMN1; SMN2HRH3MAPTHPGD | |
| SCHEMBL4042395 | 0.74 | KEAP1 (0.62) | KEAP1SMN1; SMN2HRH3HPGDDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | KEAP1 804/4885SMN1; SMN2 3335/4885HRH3 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.